27 completed, 2 recruiting, 1 terminated, 1 unknown. 31 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 31 | Completed 27, Recruiting 2, Terminated 1, Unknown 1 |
| Phase 2 | 2 | Completed 2 |
Follow Tinea: new trials by email Literature Review of Tinea trials Research Report on Tinea
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1b Study of ZYG24004 in Participants With Tinea Pedis Caused by Dermatophytes ZYG24004 1% topical film-forming formulation, ZYG24004 3% topical film-forming formulation, Placebo topical formulation - Tinea Pedis | Phase 1 | Recruiting | Sinomune Pharmaceutical Co., Ltd | 64 | 2026-07-21 | 2026-08-04 |
| Isotretinoin Versus Excimer Light an Adjuvant in Treating Onychomycosis ISOtretinoin 10 MG, excimer light, Itraconazole 200 mg - Onychomycosis | Phase 1 | Recruiting | Zagazig University | 36 | 2024-07-12 | 2026-04-23 |
| Pilot Study of Swift Microwave Device for Onychomycosis Swift Microwave treatment - weekly x 4wks, Swift Microwave treatment - Every other week x 4wks, Swift Microwave treatment - Every other week x 24wks - Onychomycosis of Toenail | Phase 1 / Phase 2 | Completed | Mediprobe Research Inc. | 39 | 2023-03-27 | 2024-11-18 |
| A Study of ATB1651 in Adults With Mild to Moderate Onychomycosis ATB1651, 2 mg/mL, ATB1651, 5 mg/mL, ATB1651, 10 mg/mL - Onychomycosis | Phase 1 | Completed | AmtixBio Co., Ltd. | 30 | 2022-03-04 | 2023-10-11 |
| Comparative Study Between Pulse Therapy With Oral Itraconazole Versus Continuous Oral Terbinafine Therapy for Treatment of Onychomycosis itraconazole, terbinafine - Onychomycosis | Phase 1 | Completed | Combined Military Hospital Abbottabad | 100 | 2022-03-01 | 2022-10-19 |
| Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis UHE-103 Cream, Naftin (naftifine hydrochloride) Cream - Tinea Cruris, Tinea Pedis | Phase 1 | Completed | Therapeutics, Inc. | 42 | 2022-02-17 | 2024-04-10 |
| Safety and Tolerability Study of SKX-16 in Subjects With Moderate to Severe Distal Subungual Onychomycosis SKX-16 (Luliconazole 10% Solution) - Onychomycosis of Toenail | Phase 1 | Completed | SATO Pharmaceutical Co., Ltd. | 19 | 2021-09-22 | 2026-08-21 |
| Alpha-bisabolol for Onychomycosis Treatment Drug recommended by the Brazilian Society of Dermatology, Alpha bisabolol product and laser, Alpha bisabolol product - Onychomycosis | Phase 1 | Completed | Universidade do Vale do Sapucai | 60 | 2020-06-01 | 2021-06-30 |
| Bioequivalence (BE) Study of Test Griseofulvin 500 Milligram (mg) Tablets Versus Reference and Dose Proportionality Study of Test Griseofulvin 250 mg and 500 mg Tablets Under Fed Conditions Griseofulvin 500 mg, Griseofulvin 250 mg, Reference Griseofulvin 500 mg - Antifungal Agents | Phase 1 | Completed | GlaxoSmithKline | 36 | 2020-01-13 | 2020-12-28 |
| Clinical Assessment of Oxiconazole Nitrate Solid Lipid Nanoparticles Loaded Gel Oxiconazole Nitrate Cream 1%, Oxiconazole nitrate SLNs loaded gel. - Tinea | Phase 1 | Completed | Minia University | 28 | 2018-07-16 | 2019-01-30 |
| A Study of the Systemic Absorption of MOB015B MOB015B - Onychomycosis | Phase 1 | Completed | Moberg Pharma AB | 20 | 2017-12-16 | 2018-05-03 |
| Evaluate Safety and Efficacy of Naftifine Hydrochloride Gel 2% and Naftin® Gel 2% in Tinea Pedis Naftifine Hydrochloride Gel 2%, Naftin® Gel 2%, Placebo Topical Gel - Tinea Pedis | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 1519 | 2014-06-27 | 2018-09-06 |
| Evaluate the Safety and Efficacy of Naftifine Hydrochloride Cream 2% and Naftin® Cream 2% in Patients With Tinea Pedis Naftifine Hydrochloride Cream 2%, Naftin® (Naftifine Hydrochloride) Cream 2%, Placebo Topical Cream - Tinea Pedis | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 890 | 2013-08-01 | 2017-05-09 |
| Pharmacokinetics and Safety Study of ME1111 in Moderate to Severe Onychomycosis Patients ME1111 solution, Vehicle Solution - Onychomycosis | Phase 1 | Completed | Meiji Seika Pharma Co., Ltd. | 24 | 2013-03-01 | 2013-12-17 |
| Evaluate the Clinical Equivalence of Two Naftifine HCl 1% Creams in Patients With Interdigital Tinea Pedis Naftifine HCl Cream 1%, Naftin® (Naftifine HCl) Cream 1%, Placebo topical cream - Tinea Pedis | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 1053 | 2012-05-01 | 2014-05-06 |
| Optimizing the Treatment of Toenail Onychomycosis Using a New Transdermal Patch Combined With Terbinafine/Ketoconazole 3 mg terbinafine and 2 mg ketoconazole containing patch, 6 mg terbinafine and 2 mg ketoconazole containing patch, 8 mg terbinafine and 2 mg ketoconazole containing patch - Onychomycosis | Phase 1 | Unknown | Taiwan Biotech Co., Ltd. | 18 | 2012-04-01 | 2012-06-11 |
| Hygienic Socks With Antifungal Agent-loaded Microcapsules for Patients With Tinea Pedis Anti-fungal agent (Clotrimazole) loaded microcapsules, Placebo - Tinea Pedis | Phase 1 | Completed | Prof. Yuen Chun-Wah | 42 | 2012-01-01 | 2013-04-02 |
| Evaluate the Safety & Bioequivalence of a Generic Butenafine Cream & Lotrimin Ultra® & Compare Both to a Vehicle Control in Treatment of Interdigital Tinea Pedis Butenafine Hydrochloride Cream, 1%, Lotrimin Ultra®, Butenafine Vehicle - Tinea Pedis | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 707 | 2012-01-01 | 2017-05-05 |
| 1320 nm Nd:YAG Laser for Improving the Appearance of Onychomycosis Laser treatment - Fungal Nail Infection | Phase 1 | Completed | University of California, Irvine | 10 | 2011-12-01 | 2022-11-01 |
| A Therapeutic Equivalence Study of Two Oxiconazole Nitrate Topical Cream Treatments for Patients With Tinea Pedis Oxiconazole Nitrate Cream 1%, Oxiconazole Nitrate Cream 1% (Oxistat®), Placebo - Tinea Pedis | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 661 | 2011-11-01 | 2014-01-22 |
Showing 20 of 31. Sign in to see all of them.
Onychomycosis (17) · Tinea Pedis (13) · Mycoses (1) · Onycholysis (1) · Tinea Cruris (1)
Bacterial Infections and Mycoses (31) · Dermatomycoses (31) · Infections (31) · Skin Diseases (31) · Skin Diseases, Infectious (31) · Skin and Connective Tissue Diseases (31) · Mycoses (30) · Nail Diseases (17) · Foot Dermatoses (13) · Foot Diseases (13) · Pathological Conditions, Signs and Symptoms (13) · Pruritus (13) · Signs and Symptoms (13) · Skin Manifestations (13)
naftifine (4) · Terbinafine (3) · butenafine (3) · Itraconazole (2) · Sodium Dodecyl Sulfate (2) · Tablets (2) · Capsules (1) · Clotrimazole (1) · Griseofulvin (1) · Isotretinoin (1) · Laser Therapy (1) · Lasers (1) · Solutions (1) · albaconazole (1) · luliconazole (1)
Sun Pharmaceutical Industries, Inc. (7) · Stiefel, a GSK Company (3) · Pfizer (2) · AmtixBio Co., Ltd. (1) · Combined Military Hospital Abbottabad (1) · Galderma R&D (1) · GlaxoSmithKline (1) · Mediprobe Research Inc. (1) · Meiji Seika Pharma Co., Ltd. (1) · Minia University (1) · Moberg Pharma AB (1) · NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.) (1) · Prof. Yuen Chun-Wah (1) · SATO Pharmaceutical Co., Ltd. (1) · Sinomune Pharmaceutical Co., Ltd (1)
United States (15) · Egypt (2) · Australia (1) · Belize (1) · Brazil (1) · Canada (1) · China (1) · Hong Kong (1) · India (1) · New Zealand (1) · Pakistan (1) · Taiwan (1)
Aditya Gupta, MD,PhD (1) · Alexa B. Kimball, MD, MPH (1) · Brent Clary, CCRC (1) · Chun Wah M. Yuen (1) · Craig Sprenger, MD (1) · David Gratton, MD (1) · Debra Breneman, MD (1) · Eduardo Tschen, MD (1) · Eric M Morrel, PhD (1) · Heba F Mansour, Ph.D (1) · Joseph Fowler, MD (1)